Literature DB >> 10229432

Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

A Spoorenberg1, D van der Heijde, E de Klerk, M Dougados, K de Vlam, H Mielants, H van der Tempel, S van der Linden.   

Abstract

Our aim was to determine whether C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) is more appropriate in measuring disease activity in ankylosing spondylitis (AS). We studied 191 consecutive outpatients with AS in The Netherlands, France, and Belgium. Patients were attending secondary and tertiary referral centers. The external criterion for disease activity was: physician and patient assessment of disease activity on a visual analog scale (VAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). In each measure we defined 3 levels of disease activity: no activity, ambiguous activity, and definite disease activity. The patients with AS (modified New York criteria) were divided into 2 groups: those with spinal involvement only (n=149) and those who also had peripheral arthritis and/or inflammatory bowel disease (IBD) (n=42). For each criterion of disease activity, the patients with no activity and with definite activity were included in receiver operator curves and used to determine cutoff values with the highest sensitivity and specificity. We also calculated Spearman correlations. The median CRP and ESR were 16 mg/l and 13 mm/h, respectively, in the spinal group and 25 mg/l and 21 mm/h, respectively, in the peripheral/IBD group. In both groups the Spearman correlation coefficients between CRP and ESR were around 0.50. There was moderate to poor correlation between CRP, ESR, and the 3 disease activity variables (0.06-0.48). Sensitivity for both ESR and CRP was 100% for physician assessment and between 44 and 78% for patient assessment of disease activity and the BASDAI, while specificity was between 44 and 84% for all disease activity measures. The positive predictive values of CRP and ESR in our setting were low (0.15-0.69). We conclude that neither CRP nor ESR is superior to assess disease activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229432

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  76 in total

1.  Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.

Authors:  Erkan Kilic; Gamze Kilic; Ozgur Akgul; Salih Ozgocmen
Journal:  Rheumatol Int       Date:  2014-11-04       Impact factor: 2.631

2.  How to diagnose axial spondyloarthropathy early.

Authors:  N Barkham; H Marzo-Ortega; D McGonagle; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study.

Authors:  Anne C Bay-Jensen; Diana J Leeming; Arndt Kleyer; Sanne S Veidal; Georg Schett; Morten A Karsdal
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

Review 4.  Ankylosing spondylitis: A state of the art factual backbone.

Authors:  Mohammad Ghasemi-Rad; Hosam Attaya; Emal Lesha; Andrea Vegh; Tooraj Maleki-Miandoab; Emad Nosair; Nariman Sepehrvand; Ali Davarian; Hamid Rajebi; Abdolghader Pakniat; Seyed Amirhossein Fazeli; Afshin Mohammadi
Journal:  World J Radiol       Date:  2015-09-28

5.  Evaluation of the Turkish version of the Dougados functional index in ankylosing spondylitis.

Authors:  Huseyin T E Ozer; Tunay Sarpel; Bozkurt Gulek; Z Nazan Alparslan; Eren Erken
Journal:  Rheumatol Int       Date:  2005-03-02       Impact factor: 2.631

6.  Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.

Authors:  Dongyi He; Qi Zhu; Quan Zhou; Qing Qi; Hongmei Sun; Liza M Zachariah; Grace Wang; John D Reveille; Yongtao Guan; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

7.  Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.

Authors:  R Landewé; B Rump; D van der Heijde; S van der Linden
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

8.  Early spondyloarthropathy: scintigraphic, biological, and clinical findings in MRI-positive patients.

Authors:  Orhan Akdeniz; Gamze Alayli; Fevziye Canbaz Tosun; Bariş Diren; Kivanç Cengiz; Mustafa Bekir Selçuk; Tevfik Sünter; Ferhan Cantürk
Journal:  Clin Rheumatol       Date:  2007-09-15       Impact factor: 2.980

9.  The relationship between enthesitis indices and disease activity parameters in patients with ankylosing spondylitis.

Authors:  Filiz Sivas; Bedriye Mermerci Başkan; Esra Erkol Inal; Lale Akbulut Aktekin; Nurdan Barça; Kürşat Ozoran; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2008-10-24       Impact factor: 2.980

10.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.